Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12047598 | 0.92 | DPP4 (0.54) | DPP4KCNH2CHRM1 | |
| SCHEMBL8214909 | 0.88 | DPP4 (0.44) | DPP4KCNH2CHRM1FAP | |
| SCHEMBL8217368 | 0.88 | DPP4 (0.44) | DPP4KCNH2CHRM1FAP | |
| SCHEMBL8204964 | 0.87 | DPP4 (0.44) | DPP4KCNH2CHRM1 | |
| SCHEMBL8219926 | 0.87 | DPP4 (0.43) | DPP4KCNH2CHRM1FAP | |
| SCHEMBL8215864 | 0.86 | DPP4 (0.52) | DPP4KCNH2FAP | |
| SCHEMBL8211822 | 0.86 | DPP4 (0.45) | DPP4KCNH2CHRM1 | |
| SCHEMBL8214761 | 0.86 | DPP4 (0.43) | DPP4KCNH2CHRM1FAP | |
| SCHEMBL8214998 | 0.84 | DPP4 (0.46) | DPP4KCNH2CHRM1FAP | |
| SCHEMBL8214971 | 0.84 | DPP4 (0.62) | DPP4KCNH2FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071583-B2 | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-06 | — | — | US | disclosed |
| US-20090325926-A1 | PYRROLO[3,2-D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| WO-2008017670-A1 | PYRROLO [3, 2 -D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325926-A1 | PYRROLO[3,2-D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | DPP4, DPP3, DPP7 | DPP4 1/4885KCNH2 3076/4885CHRM1 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.